Oncolytic Virotherapy Trials—Letter

Oncolytic virotherapy.

Oncolytic virotherapy is an emerging technology that uses engineered viruses to treat malignancies. Viruses can be designed with biological specificity to infect cancerous cells preferentially, and to replicate in these cells exclusively. Malignant cells may be killed directly by overwhelming viral infection and lysis, which releases additional viral particles to infect neighboring cells and di...

Oncolytic Virotherapy in Cancer

Oncolytic viruses are natural or genetically modified viral species that selectively infect and kill neoplastic cells. Oncolytic viruses as highly targeted agents that would mediate cancer cell-autonomous anticancer effects. The therapeutic potential of oncolytic virotherapy is not a simple consequence of the cytopathic effect, but strongly relies on the induction of an endogenous immune respon...

Oncolytic Virotherapy for Hematological Malignancies

Hematological malignancies such as leukemias, lymphomas, multiple myeloma (MM), and the myelodysplastic syndromes (MDSs) primarily affect adults and are difficult to treat. For high-risk disease, hematopoietic stem cell transplant (HCT) can be used. However, in the setting of autologous HCT, relapse due to contamination of the autograft with cancer cells remains a major challenge. Ex vivo manip...

Oncolytic Virotherapy: A Brief Overview

Oncolytic virotherapy is the use of viruses to target a tumor for infection and lysis while leaving healthy cells uninfected. The history of viral oncology dates back to the turn of the 20th century when clinicians observed spontaneous regression of tumors after vaccination with attenuated viruses [1]. Experiments were done in the 1950s using Picornaviruses but soon fell out of favour to chemot...

Oncolytic virotherapy of ovarian cancer